A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors.

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic ...

On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase. The ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 clinical trial of CT-95, a bispecific antibody designed to target ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...

Tecvvayli, Talvey, and Elrexfio demonstrate significant response rates and extended progression-free survival in heavily pretreated patients. Each bispecific antibody has a unique side effect profile, ...

IBI363 has demonstrated outstanding efficacy signals in immunotherapy (IO)-naïve melanoma patients across two earlier clinical trials (Phase 1a/ 1b study NCT05460767 and Phase 2 study NCT06081920), ...

Researchers from Sanofi SA reported the preclinical characterization of SAR-446159 (ABL-301), a bispecific antibody construct comprising an antibody targeting α-synuclein fused to an engineered ...